Holen Sie sich die Stockscreener-App
2.24
0.22%
0.005
Vorhandelsmarkt:
2.25
0.010
+0.45%
Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten
ABOS Should I Buy - intellectia.ai
Analysts’ Top Healthcare Picks: Acumen Pharmaceuticals (ABOS), High Tide (HITI) - The Globe and Mail
BTIG Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Acumen Pharmaceuticals (NASDAQ: ABOS) Aims for Late 2026 Sabirnetug Phase 2 Topline Data - Kalkine Media
Form 8K Acumen Pharmaceuticals Inc For: 16 September By Investing.com - Investing.com South Africa
BTIG reiterates Buy rating on Acumen Pharmaceuticals, $8 price target - TradingView
Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor DaySlideshow (NASDAQ:ABOS) 2026-09-16 - Seeking Alpha
Acumen Pharmaceuticals to Webcast Investor Day; ALTITUDE-AD topline expected late 2026, EBD IND targeted mid-2027 - TradingView
Citi Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Raises Target Price to $5 - Moomoo
Acumen Pharmaceuticals to host virtual investor day focusing on AβO therapies and ALTITUDE-AD study - Traders Union
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026 - The Manila Times
Acumen will meet investors online Sept. 16 - Stock Titan
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - Moomoo
An Alzheimer’s drug developer will join two live online events Sept. 9 and 10 - Stock Titan
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026 - Barchart.com
Acumen Pharmaceuticals Earnings Call: Science vs. Runway - TipRanks
Acumen (ABOS) Trading: Finishes 0.94% Lower at $3.16 on the Day; Price Setup: the Session Ends Within the Reported Technical Boundaries under the Current SnapshotChaikin Flow - dars.gov.et
Acumen Pharmaceuticals Inc (ABOS) Stock News Today - TradingKey
Acumen Pharmaceuticals (ABOS) Advances 4.7% to $2.67 as Momentum BuildsForce Index - vinanet.vn
Conferencia de resultados del T2 de 2026 de Acumen Pharmaceuticals (ABOS): lectura de datos de ALTITUDE-AD prevista para finales de 2026 - TradingKey
Acumen Pharmaceuticals (ABOS) Edges Higher: Biotech Stock Gains 1.59% as Bulls Target $2.68 ResistanceCall Wall - vinanet.vn
Citi Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $4 - moomoo.com
Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Acumen Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Acumen Pharmaceuticals Q2 EPS $(0.45) misses $(0.34) estimate - scanx.trade
Acumen Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ABOS) 2026-08-12 - Seeking Alpha
ABOS: Phase II Alzheimer's trial on track for late 2026 readout; strong cash position supports pipeline - TradingView
Acumen Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
ABOS: Phase II Alzheimer's trial on track for late 2026 readout; strong cash position and pipeline progress - TradingView
Second quarter earnings and operational progress released by Acumen Pharmaceuticals, Inc. - Traders Union
Acumen Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
Acumen Pharmaceuticals Reports Q2 Results, Advances Alzheimer’s Programs - TipRanks
Form 8K Acumen Pharmaceuticals Inc For: 12 August By Investing.com - Investing.com Australia
Acumen Pharmaceuticals Reports Second-Quarter 2026 Results and Advances Alzheimer’s Pipeline, with ALTITUDE-AD Topline Data Expected in Late 2026 - Quiver Quantitative
Acumen Pharmaceuticals Q2 net loss widens, misses analyst estimates - TradingView
Acumen Reports Q2 Net Loss as Alzheimer’s Trial Readout Nears - Quiver Quantitative
Acumen Pharmaceuticals Inc (ABOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acumen Pharmaceuticals Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Acumen Pharmaceuticals, Inc. (ABOS) stock price, news, quote and history - Yahoo Finance Australia
Acumen Pharmaceuticals (ABOS.US) will release its earnings report before the market opens on August 12. - Moomoo
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026 - The Manila Times
Enterprise value to EBITDA forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Alzheimer’s drug developer Acumen sets Aug. 12 webcast at 8 a.m. - Stock Titan
Price to book forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Acumen Pharmaceuticals (ABOS) Holds Steady at $2.24 as Key Support and Resistance Levels Come Into FocusVWAP Bounce - careplusvn.com
Acumen Pharmaceuticals (ABOS) Projected to Release Earnings on Tuesday - MarketBeat
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Acumen Pharmaceuticals Inc - TradingKey
ABOS|Acumen Pharmaceuticals Inc|Price:2.235|Chg%:+0.105 - TradingKey
ABOS|Acumen Pharmaceuticals Inc|Price:2.440|Chg%:+0.160 - TradingKey
Price to earnings forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Enterprise value to revenue forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Acumen Pharmaceuticals Inc (ABOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Institutional Confidence - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Income Statement - TradingKey
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):